BioProtein Technologies launches TRM a subsidiary dedicated to the production of genetically modified rabbit models

17-Feb-2010 - France

BioProtein Technologies announced the launch of its subsidiary: Transgenic Rabbit Models (TRM), dedicated to the development of genetically modified research models with a high value-added for the biopharmaceutical industry and academic research.

TRM provides genetically modified rabbit models for biomedical research, a species relatively underexploited until now compared to mice and rats. With the improvement of handling techniques, gene replacement and the development of specific proprietary methods for rabbits (knock-down, knock-out or knock-in), Transgenic Rabbit Models can now provide biotechnology and pharmaceutical companies or academic laboratories, with fully integrated services intended for the design and production of transgenic rabbit models for biomedical research.

Alexandre Fouassier, CEO of Transgenic Rabbit Models, declared: «Contrary to common beliefs, rabbits are not rodents. They belong to the order of lagomorphs and are phylogenetically closer to primates than rodents or ruminants. It is therefore an attractive animal for producing human glycoproteins and recombinant vaccines, our ongoing activity with BioProtein. The particularities of the rabbit and the development of specific genetic engineering tools makes it one of the most promising animal model to open new pathways of research on complex diseases like diabetes, obesity, atherosclerosis, heart diseases, major ophthalmic diseases or various cancers. With a short-time gestation and early sexual maturity, we are able to generate lines of transgenic animals in very short time. We are convinced that this market will register a very strong growth in the years to come. TRM, which has already a strong expertise in transgenesis and breeding, intends to become the undisputed leader in this field of activity.»

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances